<i>Cannabis sativa</i>: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC
<i>Cannabis sativa</i> (<i>Cannabis</i>) is one of the world’s most well-known, yet maligned plant species. However, significant recent research is starting to unveil the potential of <i>Cannabis</i> to produce secondary compounds that may offer a suite of medical...
Main Authors: | Jackson M. J. Oultram, Joseph L. Pegler, Timothy A. Bowser, Luke J. Ney, Andrew L. Eamens, Christopher P. L. Grof |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/9/3/234 |
Similar Items
-
Simultaneous Quantification of 17 Cannabinoids in Cannabis Inflorescence by Liquid Chromatography-Mass Spectrometry
by: Amitha K. Hewavitharana, et al.
Published: (2022-03-01) -
Medical Cannabis in Pediatric Oncology: Friend or Foe?
by: Megan Malach, et al.
Published: (2022-03-01) -
The Effect of Harvest Date on Temporal Cannabinoid and Biomass Production in the Floral Hemp (<i>Cannabis sativa</i> L.) Cultivars BaOx and Cherry Wine
by: Eric R. Linder, et al.
Published: (2022-10-01) -
Mechanisms of Cannabidiol (CBD) in Cancer Treatment: A Review
by: Camren G. Heider, et al.
Published: (2022-05-01) -
Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review
by: Ana M. Martins, et al.
Published: (2022-02-01)